Search results
Pulmonary Hypertension
Author(s):
Brendan P Madden
Added:
3 years ago
Article
Author(s):
Victor F Tapson
Added:
3 years ago
Chronic thromboembolic pulmonary hypertension (CTEPH) results from obstruction of the major pulmonary arteries by unresolved or organized pulmonary emboli that have become incorporated into the vessel wall, ultimately causing increased pulmonary vascular resistances. Without intervention, CTEPH is a progressive, fatal disease for which there is no proven effective medical therapy. Pulmonary…
View more
Author(s):
Athanasios Charalampopoulos
,
J Simon R Gibbs
Added:
3 years ago
Abstract
Pulmonary hypertension is a relatively common finding in patients with left heart disease and lung hypoxic disease. Nonetheless, some types of pulmonary hypertension, such as pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, are rare. Despite the rarity of these diseases their impact on patients' lives and healthcare system is significant because of…
View more
Author(s):
Irene M Lang
Added:
11 months ago
Author(s):
Irene M Lang
,
Nika Skoro-Sajer
Added:
3 years ago
Chronic thromboembolic pulmonary hypertension (CTEPH) is believed to result from single or recurrent pulmonary thromboemboli arising from sites of venous thrombosis.1 The pathogenesis of the disease has not yet been fully elucidated. Acute pulmonary embolism subsequent to deep venous thrombosis may serve as the inciting event that stimulates local factors mediating aberrant organisation of…
View more
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
4 months ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more
A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension
Author(s):
Brendan P Madden
Added:
3 years ago
Article
Author(s):
Wouter Jacobs
,
Anton Vonk-Noordegraaf
Added:
3 years ago
Abstract
Pulmonary arterial hypertension is a progressive disease of the pulmonary vasculature, ultimately leading to right heart failure and death. Current treatment is aimed at targeting three different pathways: the prostacyclin, endothelin and nitric oxide pathways. These therapies improve functional class, increase exercise capacity and improve haemodynamics. In addition, data from a meta…
View more
Author(s):
Robert Voswinckel
,
Ralph T Schermuly
,
Norbert Weissmann
,
et al
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease defined by increasing pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure. The life expectancy of patients with PAH who do not receive appropriate treatment is dramatically reduced. Guidelines for the diagnosis and treatment of PAH have been established by the American…
View more
Chronic Thromboembolic and Pulmonary Arterial Hypertension Share Acute Vasoreactivity Properties
Author(s):
Silvia Ulrich
Added:
3 years ago
Article